This is straight from the mouth of the person doing the work, Nikoletta Kallinteris, Senior Scientist of Translational Research reporting to Joe Shan, Peregrine:
David Carbone was a key KOL that knew the value of PS Targeting IP and gave some very helpful information to Biothera regarding Bavituximab and the anti-PS platform
I wonder what the late Paul Carbone would say about his son that stays quiet like Dr Jedd Wolchok and the others ....what oath is taken when one becomes an MD? I though it was something about bringing the best treatments forward and don't sell out the patients just because some John Springs Stafford friends want to make money and delay PS Targeting
_____
It is time for the FDA to allow 3D imaging from several various technologies to support the MOA of certain drugs and let us SEE the targeting of flipped PS that occurs BEFORE other protein pathways shift back to safety and restore ones immune system to optimal levels before any other toxic drugs wants to be shoved down the FDA approval line
Everyone best wake up and realize that there was a reason why CDMO Avid is being granted big contracts
I guess it they push the price up north enough, everyone becomes Wolchok like and shuts the hell up
_______
______________
June 1, 2019
Biothera Pharmaceuticals Presents Clinical Data from Phase 2 Study Evaluating the Combination of Imprime PGG and Merck’s KEYTRUDA in Triple Negative Breast Cancer at 2019 ASCO Annual Meeting